Tonix Pharmaceuticals to Showcase TNX-801 Mpox Vaccine Data at Vaccine Congress 2025
July 7th, 2025 1:15 PM
By: Newsworthy Staff
Tonix Pharmaceuticals will present preclinical data on TNX-801, a potential vaccine against mpox and other orthopoxviruses, at the Vaccine Congress 2025, highlighting its safety, immunogenicity, and efficacy.
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced that Dr. Sina Bavari, Executive Vice President of Infectious Disease Research and Development, will present new preclinical data on TNX-801 at the Vaccine Congress 2025 in Vienna on July 10. TNX-801, a recombinant horsepox virus live vaccine candidate, has demonstrated protective efficacy against mpox and other orthopoxviruses in animal models following a single dose. The vaccine platform is designed to elicit durable immune responses and has the potential to be adapted for other emerging viral threats. The presentation will cover key findings on the vaccine's safety, immunogenicity, and efficacy, as well as outline the company's plans to commence clinical trials. For more details, visit https://ibn.fm/6hDuP.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
